Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$331.94 +0.7%	$294.96	$205.87 ▼ $333.70	$43.28B	0.23	853,986 shs	431,157 shs
GILD Gilead Sciences	$111.28 -0.2%	$107.02	$66.01 ▼ $119.96	$139.01B	0.29	7.69 million shs	4.04 million shs
IBB iShares Biotechnology ETF	$130.02 +0.4%	$124.46	$107.43 ▼ $150.57	$5.47B	0.73	1.47 million shs	658,990 shs
REGN Regeneron Pharmaceuticals	$545.00 -0.5%	$549.38	$476.49 ▼ $1,211.20	$59.10B	0.33	905,431 shs	456,413 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+2.82%	+8.72%	+40.81%	+33.48%
GILD Gilead Sciences	0.00%	+0.55%	+2.07%	+3.75%	+67.10%
IBB iShares Biotechnology ETF	0.00%	+2.81%	+3.92%	+10.98%	-3.75%
REGN Regeneron Pharmaceuticals	0.00%	+4.61%	+12.39%	-4.96%	-46.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.3112 of 5 stars	2.4	4.0	0.0	4.3	3.9	2.5	0.6
GILD Gilead Sciences	4.8436 of 5 stars	1.4	3.0	4.2	4.1	4.0	2.5	3.1
IBB iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	4.946 of 5 stars	4.4	5.0	1.7	2.3	2.7	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.79	Moderate Buy	$340.00	2.43% Upside
GILD Gilead Sciences	2.78	Moderate Buy	$110.55	-0.66% Downside
IBB iShares Biotechnology ETF	2.67	Moderate Buy	$130.02	N/A
REGN Regeneron Pharmaceuticals	2.80	Moderate Buy	$813.57	49.28% Upside

Current Analyst Ratings Breakdown

Latest IBB, ALNY, GILD, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$287.00 ➝ $333.00
6/30/2025	REGN Regeneron Pharmaceuticals	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/26/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$320.00 ➝ $377.00
6/24/2025	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$300.00 ➝ $360.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
6/9/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$950.00 ➝ $800.00
6/5/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$633.00 ➝ $560.00
6/2/2025	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$700.00 ➝ $650.00
6/2/2025	REGN Regeneron Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$800.00 ➝ $600.00
6/2/2025	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$958.00 ➝ $755.00
5/30/2025	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	19.25	N/A	N/A	$0.52 per share	638.35
GILD Gilead Sciences	$28.75B	4.81	$6.84 per share	16.27	$15.44 per share	7.21
IBB iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$14.20B	4.14	$45.49 per share	11.98	$268.50 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	372.97	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	23.43	13.72	0.72	20.76%	51.93%	17.40%	8/6/2025 (Estimated)
IBB iShares Biotechnology ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	13.87	14.33	2.00	31.94%	15.27%	11.93%	8/1/2025 (Estimated)

Latest IBB, ALNY, GILD, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/1/2025	Q2 2025	REGN Regeneron Pharmaceuticals	$8.53	N/A	N/A	N/A	$3.30 billion	N/A
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.84%	N/A	66.53%	10 Years
IBB iShares Biotechnology ETF	$0.38	0.29%	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.65%	N/A	8.96%	N/A

Latest IBB, ALNY, GILD, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
GILD Gilead Sciences	1.16	1.37	1.23
IBB iShares Biotechnology ETF	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
GILD Gilead Sciences	83.67%
IBB iShares Biotechnology ETF	62.45%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
GILD Gilead Sciences	0.27%
IBB iShares Biotechnology ETF	N/A
REGN Regeneron Pharmaceuticals	7.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.43 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
IBB iShares Biotechnology ETF	N/A	42.10 million	N/A	Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable

IBB, ALNY, GILD, and REGN Headlines

Recent News About These Companies

August 22nd Options Now Available For Regeneron Pharmaceuticals, Inc. (REGN) - Nasdaq

1 hour ago | nasdaq.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Braun Stacey Associates Inc.

2 hours ago | marketbeat.com

2 Beaten-Down Stocks to Buy and Hold

3 hours ago | fool.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by IFM Investors Pty Ltd

4 hours ago | marketbeat.com

Principal Financial Group Inc. Has $82.21 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

5 hours ago | marketbeat.com

Teacher Retirement System of Texas Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

5 hours ago | marketbeat.com

REGN - Regeneron Pharmaceuticals Inc Valuation - Morningstar

July 4 at 12:06 PM | morningstar.comM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by GF Fund Management CO. LTD.

July 4 at 8:02 AM | marketbeat.com

Vontobel Holding Ltd. Has $4.66 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

July 4 at 4:44 AM | marketbeat.com

Regeneron Scores Multiple Myeloma Nod for Bispecific, Unlocking $600M Opportunity

July 3 at 4:02 PM | biospace.comB

Regeneron’s Pozelimab Study: A New Hope for Rare Disease Patients

July 3 at 12:20 PM | tipranks.com

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

July 3 at 10:20 AM | zacks.com

First Horizon Advisors Inc. Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

July 3 at 7:08 AM | marketbeat.com

Regeneron wins FDA accelerated approval for Lynozyfic in MM

July 3 at 6:46 AM | thepharmaletter.comT

Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA

July 3 at 6:46 AM | msn.com

Regeneron stock rises after FDA approval for blood cancer therapy

July 2 at 3:44 PM | investing.com

Regeneron Shares Climb Following FDA Approval of Blood Cancer Treatment

July 2 at 3:44 PM | msn.com

Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps

July 2 at 3:44 PM | msn.com

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

July 2 at 11:45 AM | wsj.com

US FDA approves Regeneron's blood cancer therapy

July 2 at 11:11 AM | reuters.com

Regeneron Pharmaceuticals Receives FDA Accelerated Approval for Lynozyfic™ in Treating Relapsed or Refractory Multiple Myeloma

July 2 at 11:11 AM | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBB, ALNY, GILD, and REGN Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$331.94 +2.17 (+0.66%)

Closing price 07/3/2025 03:39 PM Eastern

Extended Trading

$331.94 0.00 (0.00%)

As of 07/3/2025 04:05 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Gilead Sciences NASDAQ:GILD

$111.28 -0.24 (-0.21%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$111.28 0.00 (0.00%)

As of 07/3/2025 04:52 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

iShares Biotechnology ETF NASDAQ:IBB

$130.02 +0.47 (+0.36%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$130.08 +0.06 (+0.05%)

As of 07/3/2025 04:12 PM Eastern

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Regeneron Pharmaceuticals NASDAQ:REGN

$545.00 -2.74 (-0.50%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$547.81 +2.81 (+0.52%)

As of 07/3/2025 04:57 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time